nach oben

International Journal of Clinical Oncology

Erschienen in:

01.04.2014 | Original Article

Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer

verfasst von: Yiting Geng, Xiaofeng Chen, Jinrong Qiu, Yue Zhou, Jian Wang, Lingxiang Liu, Yongfeng Shao, Yongmei Yin

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Amplification and overexpression of human epidermal growth factor receptor-2 (HER-2) has been shown in subgroups of gastric cancer, correlated to more aggressive disease and predictive for the treatment with HER-2 antibodies. In this study, we examined the prognostic value of HER-2 expression in primary gastric cancer and in associated lymph node metastases and confirmed the role of HER-2 in tumor angiogenesis by examining vascular endothelial growth factor (VEGF) expression.

Methods

Immunohistochemistry was used to detect HER-2 and VEGF expression in 110 gastric cancer specimens and associated lymph node metastases and in 96 specimens of normal gastric mucosa.

Results

The expression level of HER-2 in gastric tissues was significantly higher than in normal tissues (19.1 % vs. 8.3 %; P < 0.05). HER-2 overexpression was homogeneous in primary gastric cancer and metastatic lymph nodes (P = 0.607). There was a significant positive correlation of HER-2 expression and VEGF expression (P = 0.007). HER-2 overexpression in primary tumor correlated with lymph node metastasis, distant metastasis, and American Joint Committee on Cancer (AJCC) stage. Cox regression multivariate analyses confirmed that tumor size, histological grade, lymph node ratio, AJCC stage, chemotherapy, and HER-2 expression were all prognostic factors. Patients with HER-2 positivity in both primary and metastatic tissues (+/+) had the poorest survival (OS, 12.5 months; DFS, 11.0 months) (P < 0.01).

Conclusions

HER-2 was significantly overexpressed in gastric cancer versus normal tissue and correlated with VEGF expression. HER-2 in tumor or lymph nodes was an independent negative prognostic factor.

Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5):341–354PubMedCrossRef

Normanno N, Bianco C, Strizzi L et al (2005) The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 6(3):243–257PubMedCrossRef

Rabindran SK (2005) Antitumor activity of HER-2 inhibitors. Cancer Lett 227(1):9–23PubMedCrossRef

Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19(9):1523–1529PubMedCrossRef

Hofmann M, Stoss O, Shi D et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52(7):797–805PubMedCrossRef

Tanner M, Hollmen M, Junttila TT et al (2005) Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16(2):273–278PubMedCrossRef

Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697PubMedCrossRef

Gancberg D, Di Leo A, Cardoso F et al (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13(7):1036–1043PubMedCrossRef

Gong Y, Booser DJ, Sneige N (2005) Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer (Phila) 103(9):1763–1769CrossRef

10.

Masood S, Bui MM (2000) Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30(3):259–265PubMed

11.

Tanner M, Jarvinen P, Isola J (2001) Amplification of HER-2/neu and topoisomerase II alpha in primary and metastatic breast cancer. Cancer Res 61(14):5345–5348PubMed

12.

Lower EE, Glass E, Blau R et al (2009) HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113(2):301–306PubMedCrossRef

13.

Santinelli A, Pisa E, Stramazzotti D et al (2008) HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 122(5):999–1004PubMedCrossRef

14.

Wu JM, Fackler MJ, Halushka MK et al (2008) Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14(7):1938–1946PubMedCentralPubMedCrossRef

15.

Bozzetti C, Negri FV, Lagrasta CA et al (2011) Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 104(9):1372–1376PubMedCentralPubMedCrossRef

16.

Marx AH, Tharun L, Muth J et al (2009) HER-2 amplification is highly homogeneous in gastric cancer. Hum Pathol 40(6):769–777PubMedCrossRef

17.

Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma—2nd English edition. Gastric Cancer 1(1):10–24PubMedCrossRef

18.

Zhao XL, Huang HK, Zhu ZH et al (2007) Correlation between expression of leptin and clinicopathological features and prognosis in patients with gastric cancer. J Gastroenterol Hepatol 22:1317–1321PubMedCrossRef

19.

Park DI, Yun JW, Park JH et al (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51(8):1371–1379PubMedCrossRef

20.

Yano T, Doi T, Ohtsu A et al (2006) Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15(1):65–71

21.

Zhang XL, Yang YS, Xu DP et al (2009) Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 33(10):2112–2118PubMedCrossRef

22.

Marchet A, Mocellin S, Ambrosi A et al (2008) The prognostic value of N-ratio in patients with gastric cancer: validation in a large, multicenter series. Eur J Surg Oncol 34(2):159–165PubMedCrossRef

23.

Persiani R, Rausei S, Biondi A et al (2008) Ratio of metastatic lymph nodes: impact on staging and survival of gastric cancer. Eur J Surg Oncol 34(5):519–524PubMedCrossRef

24.

Adamo V, Franchina T, Adamo B et al (2007) Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). Ann Oncol 18(suppl 6):vi11–vi15

25.

Dawood S, Gonzalez-Angulo AM, Peintinger F et al (2007) Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M.D. Anderson experience. Cancer (Phila) 110(6):1195–1200CrossRef

26.

Pagni F, Zannella S, Ronchi S et al (2012) HER2 Status of gastric carcinoma and corresponding lymph node metastasis. Pathol Oncol Res19(1):103–109

27.

Allgayer H, Babic R, Gruetzner KU et al (2007) C-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18(11):2201–2209

28.

Janjigian YY, Werner D, Pauligk C et al (2012) Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis. Ann Oncol 23(10):2656–2662PubMedCrossRef

29.

Phillips BE, Tubbs RR, Rice TW et al (2012) Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction. Dis Esophagus 26(3):299–304

30.

Konecny GE, Meng YG, Untch M et al (2004) Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10(5):1706–1716PubMedCrossRef

31.

Schoppmann SF, Tamandl D, Roberts L et al (2010) HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. Ann Oncol 21(5):955–960PubMedCrossRef

32.

Ye XW, Lu DY (2010) HER2 and VEGF expression in breast cancer and their correlations. Chin-Germ J Clin Oncol 9:208–212CrossRef

33.

Blackwell KL, Dewhirst MW, Liotcheva V et al (2004) HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res 10(12 pt 1):4083–4088PubMedCrossRef

34.

Vamesu S (2007) Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies. Rom J Morphol Embryol 48(2):121–129PubMed

35.

Ohtsu A, Shah MA, Van Cutsem E et al (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29(30):3968–3976PubMedCrossRef

36.

Martín M, Makhson A, Gligorov J et al (2012) Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. Oncologist 17(4):469–475

Titel: Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer
verfasst von: Yiting Geng
Xiaofeng Chen
Jinrong Qiu
Yue Zhou
Jian Wang
Lingxiang Liu
Yongfeng Shao
Yongmei Yin
Publikationsdatum: 01.04.2014
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2014
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-013-0542-9

Springer Medizin

Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer